Recent trends in prostate cancer in Canada
- PMID: 30994922
- DOI: 10.25318/82-003-x201900400002-eng
Recent trends in prostate cancer in Canada
Abstract
Background: Prostate cancer is the most common type of cancer in Canadian men. Screening recommendations have changed substantially over the last 25 years. Since 2011 (United States) and 2014 (Canada), taskforce guidelines have recommended against screening using the prostate-specific antigen (PSA) test in low-risk men of all ages. This work reports on trends in prostate cancer incidence, mortality, and stage at diagnosis in Canada from 1992 to 2015.
Data and methods: Prostate cancer incidence, mortality, and stage at diagnosis were retrieved from Statistics Canada's Canadian Cancer Registry and Canadian Vital Statistics - Death Database. Joinpoint analysis was used to examine trends over time.
Results: The age-standardized incidence rate (ASIR) of prostate cancer peaked in 1993 and 2001, and declined thereafter. From 2011 to 2015, the ASIR declined by 9.3% per year. The age-standardized mortality rate (ASMR) decreased continuously from 1992 to 2015, but fell most rapidly (2.9% per year) after 2001. Data from two provinces show that, from 2005 to 2015, the rate of Stage I and Stage II cancers decreased by 3.2% per year, while the rate of Stage III and Stage IV cancers remained relatively stable.
Discussion: Incidence of prostate cancer has declined substantially in recent years. Most of the decline seems to be in localized cases (Stage I and Stage II). Changes in incidence have mirrored changes to PSA screening recommendations. Future work should continue to monitor trends over time at the national level, especially as they relate to screening recommendations.
Keywords: Cancer; men’s health; prostate; prostate-specific antigen; public health; screening.
Similar articles
-
Prostate cancer incidence and mortality rates and trends in the United States and Canada.Public Health Rep. 2004 Mar-Apr;119(2):174-86. doi: 10.1177/003335490411900211. Public Health Rep. 2004. PMID: 15192905 Free PMC article.
-
Annual Report to the Nation on the Status of Cancer, part II: Recent changes in prostate cancer trends and disease characteristics.Cancer. 2018 Jul 1;124(13):2801-2814. doi: 10.1002/cncr.31549. Epub 2018 May 22. Cancer. 2018. PMID: 29786851 Free PMC article.
-
Trends in prostate cancer incidence and mortality: an analysis of mortality change by screening intensity.CMAJ. 2003 Jan 7;168(1):31-5. CMAJ. 2003. PMID: 12515782 Free PMC article.
-
Evaluation and Active Treatment versus Active Surveillance of Localized Prostate Cancer in Renal Transplant Patients in the Era of Low and Very Low Risk Prostate Cancer.J Urol. 2019 Sep;202(3):469-474. doi: 10.1097/JU.0000000000000207. Epub 2019 Aug 8. J Urol. 2019. PMID: 30835631 Review.
-
Impact of screening on prostate cancer rates and trends.Microsc Res Tech. 2000 Dec 1;51(5):415-8. doi: 10.1002/1097-0029(20001201)51:5<415::AID-JEMT2>3.0.CO;2-B. Microsc Res Tech. 2000. PMID: 11074610 Review.
Cited by
-
Impact of the COVID-19 Pandemic on Prostate Cancer Diagnosis, Staging, and Treatment: A Population-Based Study in Northern Italy.Biology (Basel). 2024 Jul 4;13(7):499. doi: 10.3390/biology13070499. Biology (Basel). 2024. PMID: 39056693 Free PMC article.
-
Acute toxicity outcomes from salvage high-dose-rate brachytherapy for locally recurrent prostate cancer after prior radiotherapy.J Contemp Brachytherapy. 2024 Apr;16(2):111-120. doi: 10.5114/jcb.2024.139278. Epub 2024 Apr 30. J Contemp Brachytherapy. 2024. PMID: 38808210 Free PMC article.
-
Secondary bladder and colorectal cancer after treatments for prostate cancer: A population based study.Cancer Med. 2024 Feb;13(3):e6922. doi: 10.1002/cam4.6922. Epub 2024 Feb 13. Cancer Med. 2024. PMID: 38351647 Free PMC article.
-
Prostate-specific Antigen Density as a Proxy for Predicting Prostate Cancer Severity: Is There Any Difference between Systematic and Targeted Biopsy?Saudi J Med Med Sci. 2023 Oct-Dec;11(4):299-304. doi: 10.4103/sjmms.sjmms_49_23. Epub 2023 Oct 6. Saudi J Med Med Sci. 2023. PMID: 37970462 Free PMC article.
-
Prostate Cancer Cells Are Sensitive to Lysosomotropic Agent Siramesine through Generation Reactive Oxygen Species and in Combination with Tyrosine Kinase Inhibitors.Cancers (Basel). 2022 Nov 8;14(22):5478. doi: 10.3390/cancers14225478. Cancers (Basel). 2022. PMID: 36428570 Free PMC article.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous